学术探索
学术期刊
新闻热点
数据分析
智能评审

CYP2C9 allelic variants:: ethnic distribution and functional significance

被引：280
作者：
Xie, HG
Prasad, HC
Kim, RB
Stein, CM
机构：
[1] Vanderbilt Univ, Sch Med, Med Ctr, Div Clin Pharmacol,Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2002年 / 54卷 / 10期
关键词：
CYP2C9; polymorphism; genotyping; allelic variants; ethnic variability; meta-analysis; pharmacogenetics;
D O I：
10.1016/S0169-409X(02)00076-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cytochrome P-450 (CYP) 2C9 CYP2C9 is a polymorphically expressed enzyme responsible for the metabolism of several clinically important drugs, some with a low therapeutic index. This review summarizes the structure-function relationship of the CYP2C9 promoter and coding regions, known polymorphisms, the functional significance of various CYP2C9 alleles in vitro and in vivo, and their population frequencies. In addition, possible molecular mechanisms underlying ethnic variability in the metabolism of CYP2C9 substrate drugs are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：1257 / 1270
页数：14
相关论文
共 83 条
[1]  
Ackermann E., 1997, European Journal of Clinical Pharmacology, V52, pA71
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]   Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis [J].
Aithal, GP ;
Day, CP ;
Leathart, JBS ;
Daly, AK .
PHARMACOGENETICS, 2000, 10 (06) :511-518
[4]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[5]   Racial background is a determinant of average warfarin dose required to maintain the INR between 2•0 and 3•0 [J].
Blann, A ;
Hewitt, J ;
Siddiqui, F ;
Bareford, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :207-209
[6]  
BROCKMOLLER J, 1995, PHARMACOGENETICS, V5, P80
[7]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[8]   CYP2C9 polymorphism and warfarin dose requirements [J].
Daly, AK ;
Day, CP ;
Aithal, GP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) :408-409
[9]   GENE STRUCTURE AND UPSTREAM REGULATORY REGIONS OF HUMAN CYP2C9 AND CYP2C18 [J].
DEMORAIS, SMF ;
SCHWEIKL, H ;
BLAISDELL, J ;
GOLDSTEIN, JA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (01) :194-201
[10]   Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
123456789